To obtain a cyclosporin composition not only stable pharmaceutically, but also having high bioavailability from a pharmacokinetic point of view compared to existing products, and enabling the individual difference in its blood level to be reduced.

This cyclosporin-contg. soft capsule is such one that (l) cyclosporin as active ingredient, (2) a cosurfactant, i.e., polyethylene glycol as hydrophilic component or propylene carbonate as non-hydrophilic component or a mixture thereof, (3) an oil component, i.e., a mixture of an ester of fatty acid and monohydric alkanol, medium fatty acid triglyceride and fatty acid monoglyceride, and (4) a compound with an HLB number of 8-17 as surfactant, are included in a gelatin film containing both polyethylene glycol and propylene glycol as plasticizer.